Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID: Platform Trial for Relapsed/Refractory Ewing Sarcoma & DSRCT
NCT07781891Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2027
- Primary completion
- Jun 2031
- Countries
- 1
01
Overview
A Phase 2 trial of 765IGF-MTX in Ewing sarcoma, desmoplastic small round cell tumor (DSRCT), small round cell sarcoma (SRBCT), sponsored by University of Texas MD Anderson Cancer Center. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
765IGF-MTX
03
Conditions
Ewing sarcomadesmoplastic small round cell tumor (DSRCT)small round cell sarcoma (SRBCT)
Beyond the preview
Go deeper on NCT07781891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07781891.